Clinical Trial Update: A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing subcutaneous daratumumab to active monitoring in high-risk smoldering multiple myeloma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smoldering Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Smoldering Multiple Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2025-12-23